Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
about
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adultsTreatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as TherapyBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewAntidepressant actions of ketamine: from molecular mechanisms to clinical practiceGABAA receptor-acting neurosteroids: a role in the development and regulation of the stress responseRapid Antidepressant Activity of Ethanol Extract of Gardenia jasminoides Ellis Is Associated with Upregulation of BDNF Expression in the Hippocampus.Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysisKetamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsKetamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.New targets for rapid antidepressant action.Riluzole likely lacks antidepressant efficacy in ketamine non-responders.Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Rodent models of treatment-resistant depression.Ketamine for depression: evidence, challenges and promiseStructural connectivity and response to ketamine therapy in major depression: A preliminary study.Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model.Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants.NMDA antagonists under investigation for the treatment of major depressive disorder.The ups and downs of modelling mood disorders in rodents.The promise of ketamine for treatment-resistant depression: current evidence and future directions.Translational psychiatry--light at the end of the tunnel.Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.mTOR in Brain Physiology and Pathologies.Treating to target in major depressive disorder: response to remission to functional recovery.New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.The Ethics of Clinical Trials Research in Severe Mood Disorders.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Mood Therapeutics: Novel Pharmacological Approaches for Treating DepressionSymptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.NMDA receptors: linking physiological output to biophysical operation.Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder.Neural Substrates of Depression and Resilience.Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition.Gene expression related to serotonergic and glutamatergic neurotransmission is altered in the flinders sensitive line rat model of depression: Effect of ketamine.Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.
P2860
Q22252957-9C482D45-2128-407D-9C7A-2C75C7500AF7Q26773084-20EE564E-938B-493A-AD35-46789DCA72CDQ26782993-55D078DF-74AA-4935-A46D-C8C590997E40Q26995879-90F5F54E-4393-4256-85E1-20C0241E3FA4Q28241963-933C0E15-7EFB-4810-BBAB-077131219A16Q30414296-FC9B68A0-2E69-40EE-91E7-D2EC63E735C8Q30906677-224FBC6E-B80B-4FBB-ADC1-DD10ECCD1629Q34241455-3BEC1509-581A-41D7-BFDC-8243D48762EDQ34400329-88978569-4D7F-4EAF-8303-14E70C85F98BQ34444632-FA1F65E9-CBAF-4C94-B7B1-3C4AE8F48004Q34475595-669BA67F-D78B-4F66-82F6-E6D0C58EE923Q34507177-03400F5D-C0DF-4702-8460-056D9D7E185CQ34989048-65A7ABBE-81E7-480D-8EC8-D72EAAF65E98Q35434690-C1C1E9AA-88F6-478A-9792-246DE9384CE2Q35547495-28C105EB-3BB1-43D2-A35D-D9B412AA0572Q35580361-3D5D7A42-95A1-46A1-BF25-4795027CA1D7Q36118741-F6A43C79-4F38-4B08-BEE9-07C874937E9DQ36387149-260BAB03-F84D-4E33-AA8B-99F4B3661D24Q37424327-CC65B575-BF7D-4D50-9817-34920F937051Q37547285-8938C401-7400-4F14-BE1C-24A008FF72D4Q37668029-9FE3737F-E96A-4A79-B214-E76B7BED7C86Q38211107-BE4B74A6-AA46-4735-BDAB-F95BFF574D46Q38250047-EAFF2066-8927-4086-BA8A-3F178EB13D24Q38343315-6698178F-344A-47DB-B616-9E29F6F23126Q38370696-8A1FB7A7-3D53-46B5-BBF5-8E598E996B1EQ38371540-815859F3-B8B0-43D4-B375-8219F9D3073DQ38565769-67684CCA-7762-417B-9120-88B898A53487Q38673546-E0CFF9B4-4018-4F92-ADFC-F95E65B60B6EQ38685420-71BE8FAE-D234-4F3D-A7C8-2D7CC3ADB9BAQ38692317-3A252B65-9457-48E0-A94C-977599A3BFCCQ38786467-F1E54CE9-5990-4C6E-B2B0-160F02C4D278Q38934855-50BD575A-AB6A-4B6A-9931-4F09BBE46E98Q38990885-3493F99B-D2BD-4B78-820B-7FA098428A8DQ39006965-8DEFA535-39BC-43F7-B995-F19CDF3A7222Q39182931-B36BEFFD-988C-466E-9350-EDFFFE9747BBQ39189451-518CDAD9-AB72-4D47-9CDE-26BF2E8EEF7CQ39233337-CF5FA495-C8C7-42A7-A2AE-DD886EDD93E5Q39295832-75D55444-14E0-4504-94A0-C839DC6071A1Q39427905-67C9531C-4F87-4627-8A1B-BF8D64E619C1Q41659149-DDABE762-201B-4913-9055-CF488B1F5054
P2860
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Glutamate receptor antagonists ...... ketamine and other compounds.
@ast
Glutamate receptor antagonists ...... ketamine and other compounds.
@en
type
label
Glutamate receptor antagonists ...... ketamine and other compounds.
@ast
Glutamate receptor antagonists ...... ketamine and other compounds.
@en
prefLabel
Glutamate receptor antagonists ...... ketamine and other compounds.
@ast
Glutamate receptor antagonists ...... ketamine and other compounds.
@en
P2093
P2860
P1476
Glutamate receptor antagonists ...... : ketamine and other compounds
@en
P2093
Carlos A Zarate
David A Luckenbaugh
Dennis S Charney
P2860
P304
P356
10.1146/ANNUREV-PHARMTOX-011613-135950
P577
2014-01-01T00:00:00Z